ERBB2 and breast carcinoma: Pertuzumab, which binds to the dimerization loop in extracellular domain II of Her-2/neu, has shown a synergistic effect in combination with trastuzumab on the clinical outcome of patients with Her-2/neu-overexpressing breast cancers [23].